Acarix Gestione

Gestione criteri di controllo 0/4

Acarix Il CEO è Aamir Mahmood, nominato in Feb2024, ha un mandato di meno di un anno. possiede direttamente 0.3% delle azioni della società, per un valore di SEK 1.01M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 2.5 anni.

Informazioni chiave

Aamir Mahmood

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.3%
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	2.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Aamir Mahmood (48 yo)

less than a year

Mandato

Mr. Aamir Mahmood serves as President and Chief Executive Officer of Acarix AB (publ) since February 1, 2024. He serves as General Manager/Vice President Americas of MicroPort CRM. He has experience in cor...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Aamir Mahmood	President & Chief Executive Officer	less than a year	Nessun dato	0.30% SEK 1.0m
Claus Bo Christensen	Founder and Interim Head of R&D	no data	Nessun dato	0.019% SEK 64.3k
Christian Lindholm	CFO & Executive VP	8.8yrs	SEK 2.28m	0.0076% SEK 25.8k
Jennifer Matson	Head of Medical Affairs	2.8yrs	Nessun dato	Nessun dato
Carma Connely	Head of Market Access & Customer Excellence	2.8yrs	Nessun dato	Nessun dato
Jeff Thomas	Head of US Sales	less than a year	Nessun dato	Nessun dato
Dwyndl Nelms	Head of QA	no data	Nessun dato	Nessun dato
George Chrysant	Chief Medical Advisor	less than a year	Nessun dato	Nessun dato

1.8yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di ACARIX non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Philip Siberg	Independent Chairman of the Board	3.5yrs	SEK 526.00k	0.038% SEK 128.6k
Fredrik Buch	Independent Director	3.5yrs	SEK 263.00k	0.11% SEK 373.8k
Louise Janssen-Counotte	Independent Director	4.5yrs	SEK 263.00k	Nessun dato
Ulf Rosén	Independent Director	10.8yrs	SEK 220.00k	0.94% SEK 3.2m
David Erlinge	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Morten Bottcher	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Peter Clemmensen	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
John Cleland	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Mikael Thorén	Independent Director	1.5yrs	SEK 154.00k	2.97% SEK 10.1m
Deepak Talreja	Medical Advisor	1.3yrs	Nessun dato	Nessun dato
Saumil Oza	Member of the Advisory Board	less than a year	Nessun dato	Nessun dato
Dave Braun	Member of the Advisory Board	less than a year	Nessun dato	Nessun dato

2.5yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ACARIX non è considerato esperto (durata media del mandato 2.5 anni), il che suggerisce un nuovo consiglio.

Acarix Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Acarix AB (publ), Annual General Meeting, May 15, 2025

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

Acarix AB (publ) Approves Board Elections

High number of new and inexperienced directors

Acarix Appoints New Members to the Advisory Board

Acarix AB (publ) Announces CEO Changes

Recent updates

Acarix AB (publ), Annual General Meeting, May 15, 2025

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: kr0.019 loss per share (vs kr0.038 loss in 3Q 2023)

New major risk - Share price stability

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)

Acarix Expands Within US Wellness Exam Market

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

New 90-day low: kr1.12

Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study

Acarix Receives US Market Approval for the CADScor System

New 90-day high: kr1.29

Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR

Third quarter 2020 earnings released: kr0.11 loss per share

Acarix AB (publ) to Report Q1, 2021 Results on May 11, 2021

New 90-day high: kr1.22

Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million.